Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Clinical trial NCT03396185 · UNKNOWN

Trial details

NCT number: NCT03396185
Sponsor: Betta Pharmaceuticals Co., Ltd.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR Gene Mutation Non Small Cell Lung Cancer Stage IIIA Non Small Cell Lung Cancer Stage IIIB

Start date: 2018-05-09
Primary completion: 2022-02-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.